TY - JOUR
AB - PharmacoEconomics & Outcomes News 594 - 9 Jan 2010 Vaccine sales worth billions to ancillary markets Highly publicised vaccines not only provide profits for pharmaceutical manufacturers, but also benefit doctors, insurance companies and retailers, according to Kalorama Information. The market research company has estimated that the ancillary services and products market linked to the seasonal-influenza virus vaccine was worth nearly $5 billion in the US in 2009. Such profits come about as a result of office-visit co-payments, retail-clinic fees and indirect shopping revenue, and are predicted to be seen again if influenza A virus H1N1 vaccines meet demand and are received well. Kalorama Information has described its estimate of the ancillary services and products market as ‘conservative’, and has noted that insurance companies can utilise publicised events, such as the influenza A virus H1N1 vaccine, to improve their public image. Waiving co-payments, for example, allows insurance companies to build their image "in a way that would take a lot of advertising to accomplish". Kalorama Information. Vaccine Sales Don’t Just Benefit Drug Makers. Media Release : 29 Oct 2009. Available from: URL: www.kaloramainformation.com 809106466 1173-5503/10/0594-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved PharmacoEconomics & Outcomes News 9 Jan 
TI - Vaccine sales worth billions to ancillary markets
JF - PharmacoEconomics & Outcomes News
DO - 10.2165/00151234-201005940-00008
DA - 2013-02-09
UR - https://www.deepdyve.com/lp/springer-journals/vaccine-sales-worth-billions-to-ancillary-markets-HcPTH1L1Hr
SP - 3
EP - 3
VL - 594
IS - 1
DP - DeepDyve
ER -